Ranbaxy family faces huge tax outgoing in deal with Daiichi Sankyo
This article was originally published in Scrip
Ranbaxy Laboratories' founding family faces the prospect of paying significant capital gains taxes after the Securities and Exchange Board of India (SEBI) rejected the company's plans to complete its sale of the company to Daiichi Sankyothrough a "block deal" on the bourses.
You may also be interested in...
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.